Metastatic Castration-resistant Prostate Cancer Clinical Trials in Lake Success, New York

4 studies are recruiting for metastatic castration-resistant prostate cancer in Lake Success, New York right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

    This study is a first-in-human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX007 in adults with metastatic castration-resistant prostate cancer (mCRPC).

    Stage
    Phase 1
    Ages
    18 to 100
    Site
    Northwell Health R.J. Zuckerberg Cancer Hospital, Lake Success, New York
    Locations
    38 in total
    Run by
    Janux Therapeutics

    See if you can join NCT05519449 on ClinicalTrials.gov

  2. A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)

    This study will assess the safety and tolerability of valemetostat in combination with darolutamide in participants with Metastatic Castration Resistant Prostate Cancer (mCRPC).

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Northwell Health Cancer Institute (START NY), Lake Success, New York
    Locations
    29 in total
    Run by
    Daiichi Sankyo

    See if you can join NCT07244341 on ClinicalTrials.gov

  3. JUR-003 in Adult Patients With Metastatic Prostate Cancer

    JUR-003-ONC-101 is a first-in-human Phase 1a/1b open-label, multicenter study to evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary anti-tumor activity of JUR-003 in patients with prostate cancer. This study is divided into 2 parts: Phase-1a Dose Escalation (Part 1), and Phase…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    START New York, Lake Success, New York
    Locations
    4 in total
    Run by
    Juri Biosciences, Inc.

    See if you can join NCT07824349 on ClinicalTrials.gov

  4. A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer

    The primary purpose of this study is to evaluate the safety, tolerability, and efficacy of SYNC-T Therapy SV-102 and to identify the maximum tolerated dose (MTD) and/or selected dose for phase 2b study.

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Northwell Health, Lake Success, New York
    Locations
    23 in total
    Run by
    Syncromune, Inc.

    See if you can join NCT06533644 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.